Advanced Search

 

Study ID Status Title Patient Level Data
104864/049 Completed A Phase I Study to Determine the Maximum Tolerated Dose of Topotecan Following Oral Administration over 5, 10 or 21 Days in Patients with Malignant Solid Tumors
104864/051 Completed An Open, Non-Comparative, Phase II Study of Topotecan Given as a Continuous 21-Day Infusion Every 28 days, to Women with Advanced Epithelial Ovarian Cancer who have failed One Prior Chemotherapy Regimen Containing Cisplatin or Carboplatin
104864/053 Completed An Open-Label, Multicenter, Non-Comparative Study of Topotecan as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) in Patients with Small Cell Lung Cancer
104864/057 Completed An Open-Label, Non-Comparative, Phase II Study of Topotecan as Single Agent, First-Line Therapy Administered as a Continuous 21-Day Infusion Every 28 Days to Patients with Stage IIIB and IV Non-Small Cell Lung Cancer.
104864/059 Completed An Open-label, Non-Comparative, Phase II Study of Topotecan as Single Agent, Second-Line Therapy Administered as a Continuous 21-Day Infusion Every 28 Days to Patients with Relapsed or Refractory Small Cell Lung Cancer
104864/065 Completed An open-label multicentre, randomised, phase II comparator study of oral topotecan versus intravenous topotecan for second-line therapy in sensitive patients with small cell lung cancer
104864/067/080 Completed An Open-Label, Multicenter, Randomized, Phase III, Comparative Study of Topotecan, as Single Agent, Second-Line Therapy Administered Intravenously or Orally as Five Daily Doses Every 21 Days in Women with Advanced Ovarian Cancer
104864/078 Completed An Open-Label, Multicenter Study of Single Agent Oral Topotecan Daily Times Five Every 21 Days For First-Line Treatment in Patients with Extensive SCLC Eligible for Oral Therapy
104864/090 Completed An Open Label, Multicenter, Randomized, Phase III Study of Hycamtin (Topotecan) as Single Agent, Second-Line Therapy (Administered Intravenously as Five Daily Doses Every 21 Days) Versus Second-Line Cyclophosphamide, Doxorubicin and Vincristine (CAV) in Patients with SCLC Who Have Relapsed At Le ...
104864/092 Completed Phase II trial with topotecan in patients with small cell lung cancer.
104864/094 Completed EORTC 08957: A phase II trial of Topotecan in combination with Cisplatin as second line treatment in small cell lung cancer (SCLC)
104864/096 Completed An open-label, multicentre, randomised, phase III study of topotecan plus cisplatin versus paclitaxel plus cisplatin for the first-line treatment of patients with advanced ovarian carcinoma.
104864/097 Completed Phase I Study of Topotecan in Cancer Patients with Hepatic or Renal Dysfunction.
104864/100 Completed A phase I study to determine the maximum tolerated doses of paclitaxel, cisplatin and topotecan (PTC) administered intravenously every 21 days as first line therapy in patients with advanced (stage III and IV) ovarian carcinoma.
104864/101 Completed A phase I study to determine the maximally tolerated dose (MTD) and sequence dependent effects of topotecan administered orally once per day for five days with a single intravenous (iv) dose of cisplatin, repeated every three weeks to subjects with malignant tumour.
104864/111 Completed An Open, Comparative, Phase II Study of Immediate Versus Delayed Treatment with Topotecan HCl Given as a Continuous 21-Day Infusion Every 28 Days to Patients with AIDS-Related Progressive Multifocal Leukoencephalopathy.
104864/111127 Completed An open-label, multicenter, non-comparative, Phase II study of oral topotecan in combination with bevacizumab for second-line treatment in subjects with relapsed small-cell Lung Cancer (SCLC)
104864/118 Completed An open-label, two period, cross over study to compare the bioavailability of a single dose of oral topotecan in the presence or absence of ranitidine
104864/151 Completed An Open-Label, Non-Comparative, Multicenter Phase II Study of Oral Topotecan as a Single Agent, Second Line Therapy Administered for Five Days in Patients with Advanced Ovarian Cancer
104864/152 Completed A Phase II study to determine the efficacy and safety of oral topotecan given once daily for 5 days with a single intravenous dose of cisplatin on Day 5 repeated every 21 days in patients with advanced non-small cell lung cancer
104864/178 Completed A Phase I study to assess the safety and tolerability of Hycamtin administered sequentially to patients with cancer of the ovary who have received carboplatin and Taxol treatment.
104864/181 Completed Phase II Study of Topotecan in Patients with Extensive Small Cell Lung Cancer
104864/191 Completed Phase I study with Hycamtin (topotecan) and simultaneous radiation in subjects with non-small cell lung cancer (NSCLC) stage IIIb.
104864/201 Completed A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS
104864/203 Completed A phase II study to determine the efficacy and safety of 2.3mg/m2 oral topotecan daily for 5 days every 21 days in patients with advanced breast cancer

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.